Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ocular Therapeut (NQ: OCUL )

20.03 USD +0.38 (+1.93%)
Official Closing Price Updated: 4:23 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 733,444
Open 19.41
Bid (Size) 19.51 (2)
Ask (Size) 20.06 (1)
Prev. Close 19.65
Today's Range 19.40 - 20.15
52wk Range 3.775 - 24.30
Shares Outstanding 37,280,054
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ocular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New Hor
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye,... 
From Business Wire News Releases
Ocular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today... 
From Business Wire News Releases

Performance

YTD
+0.50%
+0.50%
1 Month
-10.46%
-10.46%
3 Month
+94.09%
+94.09%
6 Month
+131.83%
+131.83%
1 Year
+318.16%
+318.16%

More News

Read More
Ocular TherapeutixTM Announces Exercise of Underwriters’ Option to Purchase Additional Shares
From Business Wire News Releases
Ocular Therapeutix™ Announces Submission to the FDA of a Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic
From Business Wire News Releases
Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock
From Business Wire News Releases
10 Health Care Stocks With Unusual Options Alerts In Today's Session
Tags BBIO EXAS VRTX
From Benzinga
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
From Business Wire News Releases
The OCUL Paradox: Analysts Bullish But Forecast -5.22% Fall
Tags ETFs
From ETF Channel
Ocular Therapeutix Price Target Raised to $30 from $20 at JMP Securities
Tags Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
Ocular Therapeutix Downgraded to Neutral from Buy at H.C. Wainwright
Tags Stocks / Equities
From Blogs - TalkMarkets
Benzinga's Top Upgrades, Downgrades For December 17, 2020
Tags URI T SABR
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.